Showing results (41-50 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 18, 2025
Challenging and new opportunities for prodrug technologyHelin Li, Xuelian Shen, Yu Chu, et al.
Investigational New Drugs|January 27, 2025
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancerSaisai Ma, Yichen Xu, Minmin Liu, et al.
Investigational New Drugs|January 12, 2025
Dual PTCH2 mutation [Ser391*, Leu104Pro]: unveiling a potential new genetic susceptibility factor for glioma developmentXiang Li, Yingting Wu, Tiantian Han, et al.
Investigational New Drugs|January 9, 2025
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNAYoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, et al.
Investigational New Drugs|January 3, 2025
Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysisZhaoquan Wu, Xiting Li, Rui Huang, et al.
Investigational New Drugs|January 6, 2025
Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancerRui Liu, Zhi Ji, Xia Wang, et al.
Investigational New Drugs|December 1, 2024
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective studyManyi Xu, Yanhua Wang, Ke Wang, et al.
Investigational New Drugs|December 26, 2024
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasisYue Sun, Liangliang Wei, Hao Liu, et al.
Investigational New Drugs|February 13, 2025
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II studyXin Wang, Zhigang Bai, Wei Deng, et al.
Investigational New Drugs|November 4, 2024
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trialMathilde Morisseau, Carlos Gomez-Roca, Marie Viala, et al.
Pageof 372